BioMarin Acquires Amicus Therapeutics to Bolster Rare Disease Portfolio
Event summary
- BioMarin reports 13% year-over-year revenue growth for 2025, driven by 26% growth in VOXZOGO and 9% growth in enzyme therapies.
- Company announces definitive agreement to acquire Amicus Therapeutics, expected to close in Q2 2026, for $3.7 billion in non-convertible debt.
- BioMarin withdraws ROCTAVIAN from the market, incurring $240 million in charges.
- 2026 guidance excludes Amicus acquisition contributions, with expected revenue of $3.325 to $3.425 billion.
- Key pipeline updates include Phase 3 data for VOXZOGO in hypochondroplasia and regulatory submissions for PALYNZIQ label expansion.
The big picture
BioMarin's acquisition of Amicus Therapeutics marks a strategic move to diversify its rare disease portfolio and accelerate revenue growth. The deal comes amid strong financial performance in 2025, but the company faces challenges in integrating the acquisition and sustaining innovation. The biotech sector continues to focus on rare disease therapies, with BioMarin positioning itself as a leader in this space through targeted acquisitions and pipeline advancements.
What we're watching
- Integration Challenges
- How BioMarin will integrate Amicus Therapeutics' products, Galafold and Pombiliti + Opfolda, into its existing portfolio and sustain revenue growth.
- Pipeline Progress
- Whether BioMarin can deliver on its pipeline catalysts, including Phase 3 data for VOXZOGO and regulatory submissions for PALYNZIQ, to support long-term growth.
- Financial Discipline
- The pace at which BioMarin can maintain strong operating margins and cash flow while investing in innovation and future growth.
Related topics